艾滋病是严重威胁人类健康的病毒性传染病。目前临床上抗人类免疫缺陷病毒(HIV)感染的药物主要是针对反转录酶和蛋白酶。反转录酶抑制剂和蛋白酶抑制剂的联合使用能显著降低HIV感染者的发病率和病死率,然而不良反应较大,价格昂贵,而且耐药的问题日益突出。近来一类新型抗HIV药物相继问世,其中T-20已经被美国食品药品管理 AIDS is a serious viral infection that threatens human health. Currently clinically anti-human immunodeficiency virus (HIV) infection of the drug is mainly directed against reverse transcriptase and protease. The combined use of a reverse transcriptase inhibitor and a protease inhibitor can significantly reduce the morbidity and mortality of HIV-infected individuals, however, the adverse reactions are large, expensive, and the problem of resistance is becoming increasingly prominent. Recently a new class of anti-HIV drugs have come out, including T-20 has been the United States Food and Drug Administration